ORIGINAL RESEARCH



Synthesis, antitumor activity, and structure–activity relationship of some 4*H*-pyrano[3,2-*h*]quinoline and 7*H*-pyrimido[4',5':6,5] pyrano[3,2-*h*]quinoline derivatives

Ahmed M. El-Agrody · Hisham S. M. Abd-Rabboh · Abdullah M. Al-Ghamdi

Received: 23 February 2012/Accepted: 1 June 2012 © Springer Science+Business Media, LLC 2012

Abstract Several 4*H*-pyrano[3,2-*h*]quinoline (**3a–d**, **4a**, **7a,b**, **9a–c**, **10a,b**, **11a,b**, and **13a–c**) and 7*H*-pyrimido[4',5':6,5]pyrano[3,2-*h*]quinoline derivatives (**8a–c**) were obtained by treatment of 8-hydroxyquinoline (**1a**) and 8-hydroxy-2-methylquinoline (**1b**) with α -cyano-*p*-chloro/ bromocinnamonitrile (**2a,b**) or 4*H*-pyrano[3,2-*h*]quinoline derivatives (**3a,c,d**) with different electrophilic reagents followed by nucleophilic reagents. Structures of these compounds were established on the basis of spectral data. The antitumor activity of the synthesized compounds was investigated in comparison with Vinblastine. Among them, compounds **3c,d**, **4a**, **8b**, **9b,c**, **11a,b**, and **13a,c** inhibited the growth of cancer cells compared to Vinblastine. The structure–activity relationships were discussed.

Keywords 8-Hydroxyquinoline · 8-Hydroxy-2-methylquinoline · 4*H*-pyrano[3,2-*h*]quinoline · 7*H*-pyrimido[4',5':6,5]pyrano[3, 2-*h*]quinoline · Antitumor · SAR

Introduction

Heterocyclic compounds hold a special place among pharmaceutically significant natural products and synthetic compounds (Desai and Dodiya, 2011). Nitrogen heterocyclic are abundant in nature and are of great significance to life; this is because their structural subunits exist in many

A. M. Al-Ghamdi

Chemistry Department, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia

e-mail: elagrody_am@yahoo.com

natural products such as vitamins, hormones, antibiotics, and alkaloid, as well as pharmaceuticals, herbicides, and many other compounds. Nitrogen heterocyclic containing a quinoline ring is often found in biologically active molecules (Al-Ghamdi et al., 2012; Saugues et al., 2011; Guo et al., 2011; Broch et al., 2010; Ramesh et al., 2009; Righi et al., 2008; Musiol et al., 2007, 2006). 8-Hydroxyquinoline moieties have also been shown to possess diverse therapeutic activities such as antifungal (Thomas et al., 2010), antibacterial (Chang et al., 2010; Harris and Thorarensen, 2004; Musiol et al., 2008), antiprotozoic, as well as antineoplastic (Badawey and Kappe, 1997) and antiproliferative (Mrozek-Wilczkiewicz et al., 2010; Jampilek et al., 2009) activities. In addition, the antiproliferative effects of styrylquinoline derivatives on tumor cell lines have been observed and recently reported (El-Agrody et al., 2012; Polanski, 2010; Thomas and Roy, 2008; Andrew et al., 2007; Zouhiri et al., 2005; Pommier et al., 2005). Other styrylquinoline derivatives have also gained strong attention recently due to their extensive biological activities (Larghi et al., 2009; Xin-Hua et al., 2009; Ganesh et al., 2008; Narender et al., 2006).

As a result of remarkable pharmacological efficiency of quinoline derivatives and in continuation of our program on the chemistry of 4*H*-pyran derivatives (Al-Ghamdi *et al.* 2012; El-Agrody, 1994; El-Agrody *et al.*, 1997a, b, 2000, 2001, 2002, 2011, 2012; El-Agrody and Al-Ghamdi, 2011; Sabry *et al.*, 2011; Abd-El-Aziz *et al.*, 2004, 2007; Eid *et al.*, 2003; Khafagy *et al.*, 2002; Bedair *et al.*, 2000, 2001; Sayed *et al.*, 2000), we report herein the synthesis of new 4*H*-pyrano[3,2-*h*]quinoline and 7*H*-pyrimido[4',5':6,5]pyrano[3,2-*h*]quinoline derivatives, and the evaluation of their antitumor activities. The chemical structures of the studied compounds and their structure–activity relationships (SAR) are discussed in this work.

A. M. El-Agrody (🖂) · H. S. M. Abd-Rabboh ·





Chemistry

Treatment of 8-hydroxyquinoline (1a) and 8-hydroxy-2methylquinoline (1b) with α -cyano-*p*-chloro/bromocinnamonitrile (2a,b) in ethanolic piperidine under reflux afforded 2-amino-4-(4-chloro/bromophenyl)-4*H*-pyrano[3,2-*h*]quinoline-3-carbonitrile (3a,b) and 2-amino-4-(4-chloro/bromophenyl)-9-methyl-4*H*-pyrano[3,2-*h*]quinoline-3-carbonitrile (3c,d) (Scheme 1).

Compounds **3a,c,d** were subjected to electrophilic followed by nucleophilic reactions to produce fused heterotetracyclic systems incorporating pyrimidine nucleus in addition to pyranoquinoline moiety. Thus, condensation of **3a** with benzaldehyde in ethanol and piperidine under reflux gave the 2-benzylideneamino-4-(4-chlorophenyl)-4H-pyrano[3,2-h]quinoline-3-carbonitrile (**4a**), while condensation of **3c,d** with benzaldehyde was unsuccessful; 2-benzylideneamino derivatives **4b,c** were not formed (Scheme 2). When 2-benzylideneamino-4-(4-chlorophenyl)-4*H*-pyrano [3,2-*h*]quinoline-3-carbonitrile (4a) was treated with hydrazine hydrate or phenyl hydrazine in ethanol at room temperature or under reflux, the addition product **5** was formed (R = H or Ph, respectively). From the intermediate **5**, benzaldehyde hydrazone/phenylhydrazone were eliminated to give β -enaminonitrile **3a** (Khafagy *et al.*, 2002) instead of the pyrimidopyranoquinoline derivative **6** (Scheme 2). Structure **4a** was established on the basis of spectral data.

Treatment of **3c**,**d** with acetic anhydride under reflux for 30 min afforded the *N*-acetylamino derivative **7a**,**b**, while heating of **3a**,**c**,**d** with formamide under reflux provided the aminopyrimidopyranoquinoline derivative **8a–c** (Scheme 3).

Structures **7** and **8** were established on the basis of spectral data and in conjunction with our previous work (Abd-El-Aziz *et al.*, 2004, 2007; Bedair *et al.*, 2000, 2001; Eid *et al.*, 2003; El-Agrody, 1994; El-Agrody *et al.*, 1997a, b, 2000, 2001, 2002, 2011; Khafagy *et al.*, 2002; Sayed *et al.*, 2000; Sabry *et al.*, 2011).



Scheme 2 Preparation of compound (4a)



Scheme 3 Synthetic protocol of compounds (7a,b) and (8a-c)

Treatment of **3a,c,d** with triethyl orthoformate in acetic anhydride at reflux gave the corresponding imidate derivatives **9a–c**, while reaction of **3a,c** with dimethylformaidedipentylacetal (DMF-DPA) in benzene under reflux afforded the amidine derivatives **10a,b** (Scheme 4). Structures of **9** and **10** were established on the basis of IR, ¹H NMR, ¹³C NMR, ¹³C NMR-DEPT, and MS data.

Hydrazinolysis of 4-(4-chlorophenyl)-2-ethoxymethyleneamino-4*H*-pyrano[3,2-h]quinoline-3-carbonitrile (**9a**) in ethanol at room temperature under stirring afforded the open form product 4-(4-chlorophenyl)-2-hydrazinomethyleneamino-4*H*-pyrano[3,2-h]quinoline-3-carbonitrile (**11a**) instead of the cyclized compound, aminoimino derivative **12a** (Scheme 5).

In a similar manner, reaction of **9a** with methylamine yielded the open form product 4-(4-chlorophenyl)-2-methylaminomethyleneamino-4H-pyrano[3,2-h]quinoline-3-carbonitrile (**11b**), rather than the cyclized compound, imino derivative **12b** (Scheme 5). Attempts to cyclized compounds **11a,b** by reflux in ethanolic piperidine solution were unsuccessful, the aminoimino and imino derivatives **12a,b**, respectively, were not formed (Scheme 5).

The reaction of the imidate 9a with dimethylamine in ethanol at room temperature yielded the amidine derivative



Scheme 5 Preparation of compounds (10a) and (11a,b)



10a (Scheme 5), which can also be obtained as described before from the reaction of 3a with DMF-DPA (m.p. and mixed m.p. are completely identical) (Scheme 4). The structure of **11** was supported by spectral data.

Hydrazinolysis of the amidine **10a** in ethanol at room temperature under stirring or reflux was unsuccessful, the aminoimino derivative **12a** was not formed (Scheme 5). Also, reaction of **10a** with hydrazine hydrate in toluene in the presence of *p*-toluenesulfonic acid under reflux failed (Salaheldin *et al.*, 2008), the aminoimino derivative **12a** was not formed (Scheme 5).

Treatment of the imidate 9a-c with NH₃ gas bubbled in methanol at room temperature for 1 h yielded the 8-amino-

7-(4-chlorophenyl)-7*H*-pyrimido[4',5':6,5]pyrano[3,2-*h*] quinoline (**8a**) and 2-methyl derivatives **8b**,**c**, together with the open form product, 2-aminomethyleneamino-4*H*-pyr-ano[3,2-*h*]quinoline-3-carbonitrile (**13a**) and 2-methyl derivatives **13b**,**c**. The open form product was separated from the filtrate of the reaction mixture (Scheme 6).

The tetracyclic structure **8** was supported by its independent synthesis from **3a,c,d** and formamide (Bedair *et al.*, 2000, 2001) as described before (Scheme 3) and also by cyclization of **13a–c** in ethanolic piperdine solution under reflux (Khafagy *et al.*, 2002) (m.p. and mixed m.p. are completely identical) (Scheme 6). The structure of **13** was supported on the basis of IR, ¹H NMR, ¹³C NMR, and MS data.



Scheme 6 Synthetic protocol of compounds (8a-c) and (13a-c)





When the imidate **9b,c** was treated with hydrazine hydrate or methylamine in ethanol at room temperature under stirring, the addition product **14** was formed ($\mathbf{R} = \mathbf{NH}_2$ or \mathbf{CH}_3 , respectively). From the intermediate **14**, ethyl *N*-methylformimidate or ethyl formohydrazonate was eliminated to give β -enaminonitrile **3c,d** (Khafagy *et al.*, 2002; Tacconi *et al.*, 1980) instead of the aminoimino derivatives **15a,c** or imino derivatives **15b,d**, respectively (Scheme 7).

Reaction of the imidate **9b** with dimethylamine in ethanol at room temperature under stirring afforded the amidine derivative **10b** (Scheme 7), which can be obtained as described before from the reaction of **3c** with DMF-DPA (m.p. and mixed m.p. are completely identical) (Scheme 4). Hydrazinolysis of the amidine **10b** in ethanol at room temperature under stirring or reflux was unsuccessful, the aminoimino derivative **15a** was not formed (Scheme 7). Also, reaction of **10b** with hydrazine hydrate in toluene in the presence of *p*-toluenesulfonic acid under reflux failed (Salaheldin *et al.*, 2008), the aminoimino derivative **15a** was not formed (Scheme 7).

Antitumor assays

Compounds **3a–d**, **4a**, **7a,b**, **8a,b**, **9a–c**, **10a,b 11a,b**, and **13a–c** were evaluated for human tumor cell growth inhibitory activity against three cell lines: breast adenocarcinoma (MCF-7), lung carcinoma (HCT), and hepatocellular carcinoma (HepG-2). The measurements of cell growth and the

viabilities were determined as described in the literature (Rahman *et al.*, 2001). In vitro cytotoxicity evaluation using viability assay was performed at the Regional Center for Mycology & Biotechnology (RCMP), Al-Azhar University using Vinblastine as standard drug. The inhibitory activity of the synthetic compounds **3a–d**, **4a**, **7a,b**, **8a,b**, **9a–c**, **10a,b 11a,b**, and **13a–c** against the three cell lines MCF-7, HCT, and HepG-2 are given in Table 1 and Fig. 1.

Results and discussion

Quinoline derivatives were selected for this study as their families are well-known to contain active compounds with a wide range of biological and pharmacological activities (Al-Ghamdi et al. 2012; El-Agrody et al., 2012; Saugues et al., 2011; Guo et al., 2011; Desai et al., 2011; Broch et al., 2010; Thomas et al., 2010; Chang et al., 2010; Mrozek-Wilczkiewicz et al., 2010; Jampilek et al., 2009; Ramesh et al., 2009; Larghi et al., 2009; Xin-Hua et al., 2009; Ganesh et al., 2008; Righi et al., 2008; Musiol et al., 2008, 2007, 2006; Thomas and Roy, 2008; Andrew et al., 2007; Narender et al., 2006; Zouhiri et al., 2005; Pommier et al., 2005; Harris and Thorarensen, 2004; Badawey and Kappe, 1997). In the present study, twenty compounds of 4H-pyrano[3,2-h] quinoline and 7H-pyrimido[4',5':6,5]pyrano[3,2-h]quinoline derivatives were prepared. Structures of the synthesized compounds were elucidated on the basis of IR, ¹H NMR, ¹³C NMR, ¹³C NMR-DEPT, ¹³C NMR-APT, and MS data.

Table 1	Effects of the treatment	of MCF-7,	HCT, and	HepG-2	ells with	n various	concentrations	of the	e prepared	compounds;	cytotoxicity
(IC ₅₀) as	measured by the MTT me	ethod									

Compounds	Conc. (µg/ml)	MCF-7 cell viability (%)	IC ₅₀ (µg/ml)	HCT cell viability (%)	IC ₅₀ (µg/ml)	HepG-2 cell viability (%)	IC ₅₀ (µg/ml)
Vinblastine	50	07.82	6.1	16.27	2.6	14.38	4.6
	25	15.18		21.68		16.13	
	12.5	29.60		28.20		24.25	
	6.25	48.75		38.06		45.13	
	3.125	60.35		47.54		55.00	
	1.56	76.24		53.42		72.13	
	0	100.00		100.00		100.00	
3a	50	26.79	24.9	27.40	24	52.78	W
	25	49.82		48.20		57.22	
	12.5	72.86		67.40		63.52	
	6.25	82.50		76.80		68.15	
	3.125	91.61		92.60		68.52	
	1.56	100.00		100.00		79.63	
	0	100.00		100.00		100.00	
3b	50	39.11	34.8	42.40	43.7	91.80	NA
	25	58.93		78.40		96.27	
	12.5	70.00		91.20		98.35	
	6.25	75.71		97.80		100.00	
	3.125	83.93		100.00		100.00	
	1.56	94.82		100.00		100.00	
	0	100.00		100.00		100.00	
3c	50	28.00	27.9	27.60	15.8	23.15	1.8
	25	58.20		35.80		33.70	
	12.5	71.40		55.60		35.56	
	6.25	78.20		66.80		37.59	
	3.125	87.00		79.00		42.96	
	1.56	100.00		94.00		51.85	
	0	100.00		100.00		100.00	
3d	50	41.25	38.9	36.60	22.8	21.97	5.5
	25	62.32		48.80		29.34	
	12.5	71.79		58.20		39.61	
	6.25	75.18		66.60		44.87	
	3.125	82.32		88.00		63.95	
	1.56	93.93		100.00		77.50	
	0	100.00		100.00		100.00	
4a	50	26.50	2.8	09.13	0.6	18.62	2.8
	25	33.33		11.59		31.40	
	12.5	37.17		14.76		37.86	
	6.25	40.83		19.41		42.50	
	3.125	48.33		30.22		48.92	
	1.56	55.00		38.46		56.14	
	0	100.00		100.00		100.00	

Compounds	Conc. (µg/ml)	MCF-7 cell viability (%)	IC ₅₀ (µg/ml)	HCT cell viability (%)	IC ₅₀ (µg/ml)	HepG-2 cell viability (%)	IC ₅₀ (µg/ml)
7a	50	46.17	38.6	21.98	14.6	23.78	17.8
	25	54.00		42.54		35.85	
	12.5	68.67		53.33		60.22	
	6.25	76.83		77.46		78.56	
	3.125	86.50		85.16		89.70	
	1.56	96.33		96.43		100.00	
	0	100.00		100.00		100.00	
7b	50	23.38	13.5	22.54	21.3	32.56	26.5
	25	32.13		44.52		51.20	
	12.5	51.25		71.75		68.58	
	6.25	65.75		86.83		81.60	
	3.125	79.88		95.08		90.66	
	1.56	94.75		99.84		98.78	
	0	100.00		100.00		100.00	
8a	50	45.40	44.6	26.43	19.2	64.26	W
	25	68.80		42.00		67.59	
	12.5	75.80		62.14		73.33	
	6.25	81.20		74.57		83.33	
	3.125	94.50		78.57		90.37	
	1.56	100.00		83.14		94.44	
	0	100.00		100.00		100.00	
8b	50	70.24	W	41.63	26.4	28.33	6.3
	25	81.68		51.12		37.00	
	12.5	89.23		78.88		43.67	
	6.25	94.46		90.51		50.83	
	3.125	97.28		98.78		60.17	
	1.56	100.00		100.00		68.33	
	0	100.00		100.00		100.00	
9a	50	42.96	45.4	23.85	25.7	39.44	31.1
	25	67.07		51.42		57.12	
	12.5	74.18		67.08		72.28	
	6.25	81.37		73.26		86.63	
	3.125	92.96		81.71		91.04	
	1.56	98.31		93.44		97.56	
	0	100.00		100.00		100.00	
9b	50	37.54	23.8	15.21	3.6	45.21	44.5
	25	48.62		18.40		68.96	
	12.5	63.44		25.96		79.38	
	6.25	76.56		35.32		85.13	
	3.125	87.38		54.89		96.38	
	1.56	96.12		75.53		100.00	
	0	100.00		100.00		100.00	

Table 1 continued

Table 1 continued

Compounds	Conc. (µg/ml)	MCF-7 cell viability (%)	IC ₅₀ (µg/ml)	HCT cell viability (%)	IC ₅₀ (µg/ml)	HepG-2 cell viability (%)	IC ₅₀ (µg/ml)
9c	50	56.64	W	19.79	5.8	34.64	37.1
	25	67.42		23.30		62.86	
	12.5	79.16		34.04		76.43	
	6.25	87.58		46.49		83.29	
	3.125	95.39		62.87		94.57	
	1.56	98.10		81.91		100.00	
	0	100.00		100.00		100.00	
10a	50	37.74	29.3	49.52	49.4	48.06	47.9
	25	57.96		71.31		77.82	
	12.5	75.59		77.74		85.60	
	6.25	83.53		88.10		92.98	
	3.125	92.03		98.45		98.32	
	1.56	98.68		100.00		100.00	
	0	100.00		100.00		100.00	
10b	50	34.96	24.4	30.51	28.2	68.22	W
	25	49.62		53.47		81.46	
	12.5	68.18		69.69		94.72	
	6.25	76.94		74.18		97.84	
	3.125	87.22		78.67		100.00	
	1.56	97.04		82.03		100.00	
	0	100.00		100.00		100.00	
11a	50	21.43	8.4	24.80	7.4	24.87	8.7
	25	35.18		29.20		29.08	
	12.5	45.00		36.00		36.05	
	6.25	55.00		55.60		60.92	
	3.125	66.96		65.20		78.42	
	1.56	78.75		81.40		88.16	
	0	100.00		100.00		100.00	
11b	50	16.75	6.3	11.11	2.3	09.28	1.9
	25	21.38		13.57		17.90	
	12.5	29.25		22.22		30.44	
	6.25	50.13		29.44		39.02	
	3.125	65.00		41.43		45.68	
	1.56	76.75		58.25		52.76	
	0	100.00		100.00		100.00	
13a	50	23.12	10.5	18.69	6.8	35.76	23.6
	25	37.45		21.79		43.42	
	12.5	43.62		26.31		63.94	
	6.25	67.42		52.38		76.74	
	3.125	79.73		80.21		87.36	
	1.56	91.29		94.88		96.60	
	0	100.00		100.00		100.00	

Table 1 continued

Compounds	Conc. (µg/ml)	MCF-7 cell viability (%)	IC ₅₀ (μg/ml)	HCT cell viability (%)	IC ₅₀ (µg/ml)	HepG-2 cell viability (%)	IC ₅₀ (µg/ml)
13b	50	63.60	W	35.92	21.7	41.17	32.9
	25	74.22		44.18		53.83	
	12.5	81.54		65.20		57.67	
	6.25	89.32		70.71		68.00	
	3.125	96.51		82.24		76.67	
	1.56	98.38		91.63		80.50	
	0	100.00		100.00		100.00	
13c	50	56.24	W	24.80	6.2	52.33	W
	25	69.62		34.08		60.67	
	12.5	81.18		42.86		65.50	
	6.25	89.76		49.80		81.17	
	3.125	97.32		65.00		89.33	
	1.56	100.00		86.94		98.83	
	0	100.00		100.00		100.00	

^a IC₅₀ values expressed in µg/ml as the mean values of triplicate wells from at least three experiments

NA not active

w weak activity (IC₅₀ > μ g/ml)

Compounds **3a–d**, **4a**, **7a,b**, **8a,b**, **9a–c**, **10a,b 11a,b**, and **13a–c** were tested against three tumer cell lines: MCF-7, HCT, and HepG-2. The cytotoxicity evaluation using viability assays and inhibitory activities are given in Table 1 and Fig. 1.

The results from Table 1 indicate that compound 4a was the most active compound against MCF-7 and compounds 11b,a and 13a showed very good activity, while compounds 7b, 9b,10b, 3a,c, 10a, 3b, 7a, and 3d showed moderate activities. However, compounds 8a, 9a, 8b, 9c, and 13b,c exhibited weak activities as compared with the standard drug Vinblastine. Furthermore, compounds 4a and 11b are the most active compounds against HCT, compounds 9b,c, 13c,a, and 11a had very good activities,



Fig. 1 Antitumor activity of 4*H*-pyrano[3,2-*h*]quinoline and 7*H*-pyrimido[4',5':6,5]pyrano-[3,2-*h*]quinoline derivatives

compounds 7a, 3c, 8a, 7b, 13b, 3d,a, 9a, 8b, and 10b showed moderate activities, and compounds 3b and 10a showed weak activities as compared with the standard drug Vinblastine. Finally, compounds 3c, 11b, and 4a are the most active compounds against HepG-2 and compounds 3d, 8b, and 11a exhibited very good activities, while compounds 7a, 13a, and 7b showed moderate activities. In addition, compounds 9a, 13b, 9c,b, 10a, 8a, 10b, 13c, and 3a showed weak activities, while compound 3b was inactive as compared with the standard drug Vinblastine.

SAR studies

The SAR studies of 3a and its analogs revealed that compound 4a has the highest potent antitumor activity against MCF-7 compared to other compounds 11b,a, 13a, 3a, 10a, 3b, and 9a. These data indicate that the activity of compound 4a was considerably attributed to the presence of the electron-donating group (-N=CHPh-2) in 4H-pyrano-[3,2-h]quinoline moiety, suggesting that blocking of the (-NH₂-2) group with a bulky electron-donating group might be preferred at position C-2. The blocking of the (-NH₂-2) group with other electron-donating group such as (-N=CHNHMe-2/-N=CHNHNH2-2/-N=CHNH2-2) in compounds 11b,a, and 13a, resulted in slight reduction of potency. In addition, the presence of other electrondonating group such as (-NH2-2/-N=CHNMe2-2/-NH2-2/-N =CHOEt-2) for compounds 3a, 10a, 3b, and 9a, in combination with the electron-withdrawing groups (p-Cl/

BrC₆H₄-4; –CN-3), resulted in more reduction of potency. The introduction of an electron-donating group (–CH₃-9) in combination with the electron-withdrawing groups (*p*-Cl/ BrC₆H₄-4; –CN-3) and the electron-donating groups (–NHCOMe-2/–N=CHOEt-2/–N=CHNMe₂-2/–NH₂-2/–N=C HNHNH₂-2) resulted in reduction of potency of compounds **7b**, **9b**, **10b**, **3c**, **7a**, **3d**, **13b**,**c**, and **9c**, less than its hydrogen-substituted analog, suggesting that an electrondonating group might not be preferred at position C-9. Incorporating a pyrimidine nucleus with pyranoquinoline moiety in the presence of electron-withdrawing group (*p*-Cl/BrC₆H₄-7) and electron-donating group (–NH₂-8) for compound **8a** resulted in reduction of potency. More reduction of potency with the introduction of an electrondonating group (–CH₃-2) in compound **8b** was observed.

In the case of HCT, investigation of (SAR) revealed that compounds 4a and 11b had the most potent activity against HCT compared to compound 3a and its analogs. This potency could be attributed to the presence of the electrondonating groups (-N=CHPh-2 or -N=CHNHMe-2) in 4H-pyrano[3,2-h]quinoline moiety, while the blocking of the (-NH₂-2) group with an electron-donating group such as (-N=CHNH₂-2/-N=CHNHNH₂-2) in compounds 13a and 11a resulted in slight reduction of potency. The presence of the electron-donating group (-NH₂-2) resulted in the reduction of potency for compound 3a, while blocking (-NH₂-2) group with other electron-donating group such as (-N=CHOEt-2/N=CHNMe₂-2) resulted in more reduction of potency for compounds 9a, 3b, and 10a, suggesting that there might be a size-limited pocket at position C-2. The introduction of an electron-donating group (-CH₃-9) in 4H-pyrano[3,2-h]quinoline nucleus, in combination with the electron-withdrawing groups (p-Cl/BrC₆H₄-4; -CN-3) and the electron-donating groups (-N=CHOEt-2/-N =CHNHNH₂-2), resulted in slight reduction of potency of compounds 9b,c and 13c compared to its hydrogensubstituted analog. The presence of other electron-donating groups resulted in more reduction of potency of compounds 7a, 3c, 7b, 13b, 3d, and 10b. The presence of electronwithdrawing group $(p-ClC_6H_4-7)$ and the electron-donating group $(-NH_2-8)$ in 7*H*-pyrimido[4',5':6,5]pyrano[3,2-*h*] quinoline moiety for compound 8a resulted in reduction of potency, while replacement of the hydrogen atom at position C-2 with an electron-donating group (-CH₃-2) resulted in more reduction of potency for compound 8b.

Furthermore, compounds **11b** and **4a** showed higher antitumor activities against HepG-2 than the standard drug Vinblastine. This could be attributed to the presence of the electron-donating groups (-N=CHNHMe-2) or (-N=CHPh-2) in 4*H*-pyrano[3,2-*h*]quinoline moiety, suggesting that there might be a size-limited pocket at position C-2. Blocking the $(-NH_2-2)$ with $(-N=CHNHNH_2-2)$ in compound 11a resulted in slight reduction of potency and more reduction of potency with other electron-donatgroups such as (-N=CHNH₂-2/-N=CHOEt-2/ing N=CHNMe₂-2/-NH₂-2) in compounds 13a, 9a, 10a, and **3a.b.** The introduction of an electron-donating group (-CH₃-9) in 4H-pyrano[3,2-h]quinoline nucleus, in combination with the electron-withdrawing groups (p-Cl/ BrC_6H_4-4 ; -CN-3) and the electron-donating group (-NH₂-2) for compounds 3c,d, showed antitumor activity against (HepG-2) higher than or closer to that of the standard drug Vinblastine, suggesting that there might be a size-limited pocket at position C-4. The presence of other electron-donating groups such as (-NHCOMe-2/-N=CH NH₂-2/-N=CHOEt-2/-N=CHNMe₂-2/-N=CHNH₂-2) in compounds 7a,b, 13b, 9c,b, 10b, and 13c, resulted in more reduction of potency. In addition, the presence of an electron-withdrawing group $(p-ClC_6H_4-7)$ and the electrondonating group (-NH₂-8) in 7H-pyrimido[4',5':6,5]-pyrano [3,2-*h*]quinoline moiety for compound **8a** resulted in strong reduction of potency, while replacement of the hydrogen atom at position C-2 with the electron-donating group (-CH₃) resulted in strong improvement of potency for compound **8b**, suggesting that an electron-donating group might be preferred at position C-2.

Conclusions

Our interest in the synthesis of quinoline derivatives is to focus on their antitumor activities as a part of our recent research line that aims at the development of new heterocyclic compounds as strong potent antitumor agents (Al-Ghamdi et al., 2012; El-Agrody et al., 2012). Thus, in this paper we revealed the synthesis of some 4H-pyrano-[3,2-h]quinoline and 7*H*-pyrimido[4',5':6,5]pyrano[3,2-h]quinoline derivatives, followed by antitumor evaluation for all of the novel compounds. Twenty compounds of 4*H*-pyrano[3,2-*h*]quinoline and 7*H*-pyrimido[4',5':6,5]pyrano[3,2-h]quinoline derivatives were prepared and their structures were elucidated on the basis of IR, ¹H NMR, ¹³C NMR, ¹³C NMR-DEPT, and MS data. Compounds 4a, 11b,a, and 13a had the most potent antitumor activities against MCF-7 and compounds 4a, 11b, 9b,c, 11a, and 13a,c had the most potent activities against HCT, while compounds 3c, 11b, 4a 3d, 8b, and 11a had the most potent antitumor activities against HepG-2. A more extensive study is also warranted to determine additional antitumor parameters in order to give a deeper insight to its structure-activity relationship and to optimize the effectiveness of this series of molecules, which can then be used in bigger scenarios such as drug design or development of antitumor therapeutics.

Experimental

Melting points were determined with a Stuart Scientific Co. Ltd apparatus. IR spectra were determined as KBr pellets on a Jasco FT/IR 460 plus spectrophotometer. ¹H NMR and ¹³C NMR spectra were recorded using a Bruker AV 500 MHz spectrometer. ¹³C NMR spectra were obtained using distortionless enhancement by polarization transfer (DEPT), where the signals of CH & CH₃ carbon atoms appear normal (up) and the signals of carbon atoms in CH₂ environments appear negative (down). The MS were measured on a Shimadzu GC/MS-QP5050A spectrometer. Elemental analyses were performed on a Perkin-Elmer 240 microanalyser.

Synthesis of 4*H*-pyrano[3,2-*h*]quinoline-3-carbonitrile derivatives (**3a-d**)

Prepared as previously described (El-Agrody and Al-Ghamdi, 2011).

2-Benzylideneamino-4-(4-chlorophenyl)-4H-pyrano [3,2-h]quinoline-3-carbonitrile (4a)

A mixture of **3a** (0.01 mol), benzaldehyde (0.01 mol), ethanol (20 ml), and piperidine (0.5 ml) was refluxed for 2 h. The solid product was collected by filtration and crystallized from ethanol giving 4a as yellow crystals; m.p. 185–186 °C; IR (KBr) υ (cm⁻¹): 3097, 3065, 3033, 2941, 2915 (CH), 2227 (CN); ¹H NMR (500 MHz) (CDCl₃) δ: 9.28 (s, 1H, N=CH), 8.10–7.05 (m, 14H, aromatic), 5.08 (s, 1H, H-4); ¹³C NMR (125 MHz) (CDCl₃) δ (ppm): 163.87 (C-2), 159.91 (=CH), 158.25 (C-10b), 152.10 (C-9), 134.63 (C-10a), 135.35 (C-7), 129.37 (C-5), 128.92 (C-6a), 122.29 (C-4a), 119.65 (CN), 113.43 (C-8), 112.33 (C-6), 83.42 (C-3), 43.70 (C-4), 141.18, 131.84, 130.73, 130.57, 130.10, 129.85, 129.56, 126.74; MS m/z (%): 423 (M⁺+2, 8.02), 421 (M⁺, 23.35), 310 (100), 207 (3), 177 (14), 111 (26), 50 (21); Anal. Calcd for C₂₆H₁₆ClN₃O: C, 74.02; H, 3.82; N, 9.96. Found: C, 74.08; H, 3.88; N, 10.02 %.

Reaction of 4a with hydrazine derivatives

A mixture of 2-benzylideneamino-4-(4-chlorophenyl)-4*H*-pyrano[3,2-*h*]quinoline-3-carbonitrile (**4a**) (0.01 mol) and hydrazine hydrate or phenyl hydrazine (0.01 mol) in EtOH (20 ml) was stirred at room temperature or refluxed for 2 h to give **3a** (m.p. and mixed m.p. are completely identical) yielding (83 %).

Reaction of β -enaminonitrile (**3c**,**d**) with acetic anhydride

A solution of β -enaminonitrile **3c** or **3d** (0.01 mol) in Ac₂O (20 ml) was heated under reflux for 30 min. The solid product was filtered, washed with cooled EtOH, dried and recrystallized from proper solvent to give **7a**,**b**. The physical and spectral data of compounds **7a**,**b** are as follows:

2-Acetylamino-4-(4-chlorophenyl)-9-methyl-4H-pyrano [3,2-h]quinoline-3-carbonitrile (7a)

Light brown crystals from ethanol; m.p. 225–226 °C; 83 %; IR (KBr) ν (cm⁻¹): 3383 (NH), 3060, 3023, 2940, 2820 (CH stretching), 2214 (CN), 1657 (CO); ¹H NMR (500 MHz) (CDCl₃) δ : 10.30 (bs, 1H, NH), 8.08-7.10 (m, 8H, aromatic), 5.07 (s, 1H, H-4), 2.84 (s, 3H, CH₃), 2.27 (s, 3H, COCH₃); ¹³C NMR (125 MHz) (CDCl₃) δ : 169.21 (CO), 160.57 (C-2), 151.40 (C-9), 143.02 (C-10b), 137.32 (C-10a), 136.71 (C-7), 129.42 (C-5), 128.82 (C-6a), 124.62 (C-8), 123.72 (C-4a), 120.42 (C-6), 116.41 (CN), 61.57 (C-3), 43.19 (C-4), 25.19 (CH₃), 23.48 (CH₃), 140.94, 133.95, 129.61, 125.70 (aromatic); MS *m*/*z* (%): 391 (M⁺+2, 7), 389 (M⁺), (21), 278 (100), 236 (8), 209 (12), 111 (45), 75 (25); Anal. Calcd for C₂₂H₁₆ClN₃O₂: C, 67.78; H, 4.14; N, 10.78. Found: C, 67.80; H, 4.17; N, 10.81 %.

2-Acetylamino-4-(4-bromophenyl)-9-methyl-4H-pyrano [3,2-h]quinoline-3-carbonitrile (**7b**)

Light brown crystals from ethanol m.p. 249–250 °C; 80 %; IR (KBr) v (cm⁻¹): 3320 (NH), 3050, 2975, 2861 (CH), 2189 (CN), 1657 (CO); ¹H NMR (500 MHz) (CDCl₃) δ : 8.60 (bs, 1H, NH), 7.93-7.04 (m, 8H, aromatic), 5.24 (s, 1H, H-4), 2.72 (s, 3H, CH₃), 2.33 (s, 3H, COCH₃); ¹³C NMR (125 MHz) (CDCl₃) δ : 165.12 (CO), 162.48 (C-2), 160.00 (C-9), 158.28 (C-10b), 135.87 (C-10a), 131.52 (C-7), 126.55 (C-5), 126.06 (C-6a), 124.03 (C-8), 123.80 (C-4a), 121.82 (C-6), 120.95 (CN), 63.20 (C-3), 39.23 (C-4), 25.52 (CH₃), 21.37 (CH₃), 144.21, 138.18, 130.30, 123.02 (aromatic); MS *m*/*z* (%): 435 (M⁺+2, 17), 433 (M⁺, 15), 278 (100), 209 (14), 184 (15), 149 (31), 79 (70); Anal. Calcd for C₂₂H₁₆BrN₃O₂: C, 60.84; H, 3.71; N, 9.68. Found: C, 60.85; H, 3.73; N, 9.70 %.

Reaction of β -enaminonitrile (**3a**,c,d) with formamide

A mixture of β -enaminonitrile **3a,c,d** (0.01 mol) and formamide (20 ml) was refluxed for 2 h. The solid product was filtered, washed with cooled EtOH, dried and recrystallized from proper solvent to give **8a–c**. The physical and spectral data of compounds **8a–c** are as follows:

8-Amino-7-(4-chlorophenyl)-7H-pyrimido [4',5':6,5]pyrano[3,2-h]quinoline (**8a**)

Colorless needles from benzene; m.p. 298–299 °C; 69 %; IR (cm⁻¹) in KBr: 3433, 3290, 3195, (NH₂), 3097, 2950, 2897,(CH), 1638 (C=N); ¹H NMR (500 MHz) (CDCl₃) δ : 9.00 (s, 1H, H-10), 8.37–7.34 (m, 9H, aromatic), 6.85 (bs, 2H, NH₂), 5.50 (s, 1H, H-4); ¹³C NMR (125 MHz) (CDCl₃) δ : 162.70 (C-11a), 162.46 (C-8), 156.93 (C-10), 150.49 (C-1b), 144.14 (C-2), 138.09 (C-1a), 135.95 (C-4), 127.83 (C-6), 126.75 (C-4a), 123.76 (C-6a), 122.76 (C-3), 122.20 (C-5), 95.22 (C-7a), 37.86 (C-7), 143.01, 131.69, 129.47, 128.68 (aromatic); MS *m*/*z* (%): 362 (M⁺+2, 8), 360 (M⁺, 26), 249 (100), 222 (25), 194 (12), 111 (8), 75 (12), Anal. Calcd for C₂₀H₁₃ClN₄O: C, 66.58; H, 3.63; N, 15.53. Found: C, 66.03; H, 3.63; N, 15.21 %.

8-Amino-7-(4-chlorophenyl)-2-methyl-7Hpyrimido[4',5':6,5]pyrano[3,2-h]quinoline (**8b**)

Colorless needles from benzene; m.p. 288–289 °C; 67 %; IR (cm⁻¹) in KBr: 3420, 3320, 3220, (NH₂), 3091, 2945, 2897,(CH), 1654 (C=N); ¹H NMR (500 MHz) (DMSO-d₆) δ : 8.20 (s, 1H, H-10), 8.24–7.28 (m, 8H, aromatic), 6.94 (bs, 2H, NH₂, cancelled by D₂O), 5.46 (s, 1H, H-4), 2.74 (s, 3H, CH₃); ¹³C NMR (125 MHz) (DMSO-d₆) δ : 162.67 (C-11a), 162.51 (C-8), 159.05 (C-10), 156.84 (C-2), 143.70 (C-1b), 137.57 (C-1a), 136.05 (C-4), 126.13 (C-6), 125.70 (C-4a), 123.51 (C-6a), 122.83 (C-3), 120.20 (C-5), 95.29 (C-7a), 37.85 (C-7), 24.97 (CH₃), 143.13, 131.63, 129.41, 128.88 (aromatic); MS *m*/*z* (%): 376 (M⁺+2, 8.25), 374 (M⁺, 20.30), 263 (100), 236 (33), 209 (18), 154 (6), 111 (46), 74 (55), 50 (28); Anal. Calcd for C₂₁H₁₅ClN₄O: C, 67.29; H, 4.03; N, 14.95. Found: C, 67.48; H, 3.99; N, 14.98 %.

8-Amino-7-(4-bromophenyl)-2-methyl-7H-pyrimido [4',5':6,5]pyrano[3,2-h]quinoline (**8c**)

Colorless crystals from benzene; m.p. 292–293 °C; 71 %; IR (cm⁻¹) in KBr: 3095, 2947, 2899 (CH), 3391, 3318, 3193 (NH₂), 1638 (C=N); MS *m*/*z* (%): 420 (M⁺+2, 20.6), 418 (M⁺, 18.6), 263 (100), 263 (20.6), 126 (8.2), 77 (6.2); Anal. Calcd for C₂₁H₁₅BrN₄O: C, 60.16; H, 3.61; N, 13.36. Found: C, 60.32; H, 3.72; N, 13.46 %.

Reaction of β -enaminonitrile (**3a**,**c**,**d**) with triethyl orthoformate

A mixture of β -enaminonitrile **3a,c,d** (0.01 mol), triethyl orthoformate (0.01 mol), and acetic anhydride (30 ml) was refluxed for 3 h. The solvent was removed under reduced pressure and the resulting solid was recrystallized from

proper solvent to give **9a–c**. The physical and spectral data of the compounds **9a–c** are as follows:

4-(4-Chlorophenyl)-2-ethoxymethyleneamino-4H-pyrano [3,2-h]quinoline-3-carbonitrile (**9a**)

Colorless needles from benzene; m.p. 228–229 °C; 83 %; IR (KBr) v (cm⁻¹): 3044, 2987, 2936, 2903, 2864 (CH), 2205 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.92 (s, 1H, N=CH), 8.68–7.00 (m, 9H, aromatic), 4.98 (s, 1H, H-4), 4.40 (q, 2H, CH₂, J = 7.5 Hz), 1.33 (t, 3H, CH₃, J = 7.5 Hz); ¹³C NMR (125 MHz) (CDCl₃) δ : 160.68 (N=CH), 157.94 (C-2), 150.77 (C-10b), 143.93 (C-9), 138.55 (C-10a), 135.93 (C-7), 129.58 (C-5), 128.46 (C-6a), 124.77 (C-4a), 122.22 (C-8), 119.96 (C-6), 117.89 (CN), 80.19 (C-3), 64.29 (CH₂), 43.24 (C-4), 13.95 (CH₃), 141.80, 133.75, 129.74, 126.74 (aromatic); MS *m*/*z* (%): 391 (M⁺+2, 10), 389 (M⁺, 29), 278 (100), 222 (84), 140 (26), 75 (33); Anal. Calcd for C₂₂H₁₆ClN₃O₂: C, 67.78; H, 4.14; N, 10.78. Found: 68.61; H, 4.82; N, 11.46 %.

4-(4-Chlorophenyl)-2-ethoxymethyleneamino-9-methyl-4H-pyrano[3,2-h]quinoline-3-carbonitrile (**9b**)

Colorless needles from benzene; m.p. 225-226 °C; 82 %; IR (KBr) v (cm⁻¹): 3049, 2985, 2935, 2867 (CH), 2207 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.87 (s, 1H, N=CH), 8.06-7.05 (m, 8H, aromatic), 5.03 (s, 1H, H-4), 4.51 (q, 2H, CH₂, J = 7.5 Hz), 2.85 (s, 3H, CH₃), 1.44 (t, 3H, CH₃, J = 7.5 Hz); ¹³C NMR (125 MHz) (CDCl₃) δ: 160.82 (N=CH), 159.99 (C-2), 157.80 (C-9), 143.30 (C-10b), 141.86 (C-10a), 136.28 (C-7), 129.23 (C-5), 126.71 (C-6a), 124.00 (C-8), 123.11 (C-6), 120.20 (C-4a), 117.92 (CN), 80.46 (C-3), 64.28 (CH₂), 43.15 (C-4), 25.54 (CH₃), 13.95 (CH₃), 133.71, 129.66, 129.51, 125.87 (aromatic); ¹³ C NMR-DEPT spectrum at 135° CH, CH₃ [positive (up)], CH₂ [negative (down)], revealed the following signals at δ 160.82 (N=CH \uparrow), 136.28 (C-7 \uparrow), 129.51 (aromatic \uparrow) 129.23 (C-5 \uparrow), 125.87 (aromatic \uparrow) 124.00 (C-8 ↑), 123.11 (C-6 ↑), 64.28 (CH₂ ↓), 43.15 (C-4 \uparrow), 25.54 (CH₃ \uparrow), 13.95 (CH₃ \uparrow). In the DEPT spectrum at 90° only CH signals are positive (up) and showed δ 160.82 (N=CH \uparrow), 136.28 (C-7 \uparrow), 129.51 (aromatic \uparrow) 129.23 (C-5 \uparrow), 125.87 (aromatic \uparrow) 124.00 (C-8 \uparrow), 123.11 (C-6 \uparrow), 43.15 (C-4 \uparrow). In the DEPT spectrum at 45° (CH, CH₂ and CH₃ positive) revealed signals at δ 160.82 (N=CH ↑), 136.28 (C-7 ↑), 129.51 (aromatic ↑) 129.23 (C-5 \uparrow), 125.87 (aromatic \uparrow) 124.00 (C-8 \uparrow), 123.11 (C-6 [↑]), 64.28 (CH₂ [↑]), 43.15 (C-4 [↑]), 25.54 (CH₃ [↑]), 13.95 (CH₃ \uparrow); MS m/z (%): 405 (M⁺+2, 11), 403 (M⁺, 28), 292 (100), 236 (80), 154 (11), 75 (14); Anal. Calcd for C₂₃H₁₈ClN₃O₂: C, 68.40; H, 4.49; N, 10.40. Found: C, 69.33; H, 4.47; N, 10.65 %.

4-(4-Bromophenyl)-2-ethoxymethyleneamino-9-methyl-4H-pyrano[3,2-h]quinoline-3-carbonitrile (**9**c)

Colorless needles from benzene; m.p. 217–218 °C; 81 %; IR (KBr) v (cm⁻¹): 3035, 2933, 2931, 2864 (CH), 2208 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.84 (s, 1H, N=CH), 8.05-7.03 (m, 8H, aromatic), 5.01 (s, 1H, H-4), 4.50 (q, 2H, CH_2 , J = 7 Hz), 2.83 (s, 3H, CH_3), 1.43 (t, 3H, CH_3 , J = 7 Hz); ¹³C NMR (125 MHz) (CDCl₃) δ : 160.76 (N=CH), 159.98 (C-2), 157.80 (C-9), 143.42 (C-10b), 142.39 (C-10a), 136.18 (C-7), 126.71 (C-5), 125.80 (C-6a), 124.01 (C-8), 123.09 (C-6), 120.02 (C-4a), 117.97 (CN), 80.38 (C-3), 64.28 (CH₂), 43.22 (C-4), 25.59 (CH₃), 13.95 (CH₃), 137.79, 132.18, 130.01, 121.83 (aromatic); ¹³C NMR-DEPT spectrum at 135° CH, CH₃ [positive (up)], CH₂ [negative (down)], revealed the following signals at δ 160.76 (N=CH \uparrow), 136.18 (C-7 [†]), 132.18 (aromatic [†]) 130.01 (aromatic [†]), 126.71 (C-5 [↑]), 124.01 (C-8 [↑]), 123.09 (C-6 [↑]), 64.28 (CH₂ ↓), 43.22 (C-4 \uparrow), 25.59 (CH₃ \uparrow), 13.95 (CH₃ \uparrow). In the DEPT spectrum at 90° only CH signals are positive (up) and showed δ 160.76 (N=CH \uparrow), 136.18 (C-7 \uparrow), 132.18 (aromatic \uparrow) 130.01 (aromatic \uparrow), 126.71(C-5 [↑]), 124.01 (C-8 [↑]), 123.09 (C-6 [↑]), 43.22 (C-4 [↑]). In the DEPT spectrum at 45° (CH, CH₂ and CH₃ positive) revealed signals at δ 160.76 (N=CH \uparrow), 136.18 (C-7 \uparrow), 132.18 (aromatic ↑) 130.01 (aromatic ↑), 126.71(C-5 ↑), 124.01 (C-8 \uparrow), 123.09 (C-6 \uparrow), 64.28 (CH₂ \uparrow), 43.22 (C-4 \uparrow), 25.59 (CH₃) ↑), 13.95 (CH₃ ↑); MS m/z (%): 449 (M⁺+2, 23), 447 (M⁺, 29), 292 (100), 264 (14), 236 (82), 157 (7), 66 (15); Anal. Calcd for C₂₃H₁₈BrN₃O₂: C, 61.62; H, 4.05; N, 9.37. Found: C, 61.44; H, 4.45; N, 9.77 %.

Preparation of compounds 10a,b

A mixture of β -enaminonitrile **3a** or **3c** (0.01 mol), DMF-DPA (0.01 mol), and benzene (30 ml) was refluxed for 3 h. The solvent was removed under reduced pressure and the resulting solid was recrystallized from proper solvent to give **10a**,**b**. The physical and spectral data of the compounds **10a**,**b** are as follows:

4-(4-Chlorophenyl)-2-dimethylaminomethyleneamino-4Hpyrano[3,2-h]quinoline-3-carbonitrile (**10a**)

Colorless needles from benzene; m.p. 210–211 °C; 83 %; IR (KBr) v (cm⁻¹): 3015, 2921, 2850, 2808 (CH), 2196 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.89 (s, 1H, N=CH), 8.88–7.02 (m, 9H, aromatic), 4.91 (s, 1H, H-4), 3.14, 3.08 (s, 6H, 2CH₃); ¹³C NMR (125 MHz) (CDCl₃) δ : 160.00 (N=CH), 154.54 (C-2), 150.99 (C-10b), 144.27 (C-9), 138.72 (C-10a), 136.16 (C-7), 129.16 (C-5), 128.34 (C-6a), 124.07 (C-4a), 122.18 (C-8), 121.87 (C-6), 120.11 (CN), 73.43 (C-3), 43.24 (CH₃), 41.17 (CH₃), 34.91 (C-4), 142.93, 133.24, 129.65, 127.00 (aromatic); MS *m/z* (%): 390 (M⁺+2, 7), 388 (M⁺, 20), 277 (100), 222 (6), 178 (7), 75 (9); Anal. Calcd for $C_{22}H_{17}ClN_4O$: C, 67.95; H, 4.41; N, 14.41. Found: C, 68.01; H, 4.22; N, 14.40 %.

4-(4-Chlorophenyl)-2-dimethylaminomethyleneamino-9methyl-4H-pyrano-[3,2-h]quinoline-3-carbonitrile (10b)

Colorless needles from benzene; m.p. 260–261 °C; 81 %; IR (KBr) v (cm⁻¹): 3049, 2997, 2893, 2912, 2810 (CH), 2195 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.56 (s, 1H, N=CH), 7.93-6.95 (m, 8H, aromatic), 4.88 (s, 1H, H-4), 3.14, 3.08 (s, 6H, 2CH₃), 2.73 (s, 3H, CH₃); ¹³C NMR (125 MHz) (CDCl₃) δ : 160.01 (N=CH), 159.48 (C-2), 154.64 (C-9), 144.27 (C-10b), 143.04 (C-10a), 138.17 (C-7), 129.56 (C-5), 126.57 (C-6a), 126.01 (C-8), 123.28 (C-4a), 122.72 (C-6), 120.22 (CN), 73.44 (C-3), 43.26 (CH₃), 41.18 (CH₃), 34.86 (C-4), 25.78 (CH₃), 143.7; MS *m*/*z* (%): 404 (M⁺+2, 8), 402 (M⁺, 26), 291 (100), 236 (5), 188 (6), 111 (91), 75 (65); Anal. Calcd for C₂₃H₁₉ClN₄O: C, 68.57; H, 4.75; N, 13.91. Found: C, 68.22; H, 4.43; N, 13.85 %.

Reaction of 9a with hydrazine hydrate and methylamine

A mixture of imadate 9a (0.01 mol) and hydrazine hydrate or methylamine (0.01 mol) in ethanol (30 ml) was stirred at room temperature for 1 h. The solid product was collected and recrystallized from proper solvent to give **11a**,**b**. The physical and spectra data of the compounds **11a**,**b** are as follows:

4-(4-Chlorophenyl)-2-(hydrazinomethyleneamino)-4H-pyrano[3,2-h]quinoline-3-carbonitrile (11a)

Colorless needles from benzene; m.p. 203–204 °C; 81 %; IR (KBr) v (cm⁻¹): 3400, 3316, 3200 (NH & NH₂), 3051, 2940, 2815 (CH), 2178 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 9.14 (s, 1H, N=CH), 8.91–7.01 (m, 9H, aromatic), 5.99 (bs, 2H, NH₂), 5.00 (s, 1H, H-4), 4.87 (bs, 1H, NH); ¹³C NMR (125 MHz) (CDCl₃) δ : 159.94 (N=CH), 158.18 (C-2), 156.94 (C-10b), 151.10 (C-9), 138.45 (C-10a), 136.13 (C-7), 129.44 (C-5), 128.28 (C-6a), 123.81 (C-4a), 122.19 (C-8), 121.24 (C-6), 120.04 (CN), 97.56 (C-3), 41.25 (C-4), 143.57, 133.66, 129.77, 126.59 (aromatic); MS *m*/*z* (%): 375 (M⁺, 7), 268 (100), 232 (6), 175 (27), 101 (41), 75 (3); Anal. Calcd for C₂₀H₁₄ClN₅O: C, 63.92; H, 3.75; N, 18.64. Found: C, 63.51; H, 3.17; N, 18.41 %.

4-(4-Chlorophenyl)-2-(methylaminomethyleneamino)-4H-pyrano[3,2-h]quinoline-3-carbonitrile (**11b**)

Colorless needles from benzene; m.p. 201–202 °C; 81 %; IR (KBr) v (cm⁻¹): 3338 (NH), 3123, 3076, 2868 (CH),

2185 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 9.15 (s, 1H, N=CH), 8.95-7.03 (m, 9H, aromatic), 5.05 (s, 1H, NH), 4.85 (s, 1H, H-4), 3.36 (s, 3H, CH₃); ¹³C NMR (125 MHz) (CDCl₃) δ : 159.70 (N=CH), 157.50 (C-2), 150.95 (C-10b), 150.52 (C-9), 138.65 (C-10a), 136.12 (C-7), 128.34 (C-5), 127.04 (C-6a), 123.93 (C-4a), 122.15 (C-8), 121.20 (C-6), 119.80 (CN), 97.80 (C-3), 41.24 (C-4), 143.76, 133.59, 129.42, 126.86 (aromatic); MS *m*/*z* (%): 376 (M⁺+2, 7), 374 (M⁺, 21), 268 (10), 222 (100), 184 (23), 139 (31), 75 (35); Anal. Calcd for C₂₁H₁₅ClN₄O: C, 67.29; H, 4.03; N, 14.95. Found: C, 66.44; H, 3.57; N, 14.33 %.

Reaction of **9a–c** with ammonia

Method (a)

A mixture of imadate **9a–c** (0.01 mol) and NH₃ gas bubbled in methanol (30 ml) was stirred for 1 h and then the mixture was left overnight. The solid product was collected and recrystallized from proper solvent to give **8a–c**. Compounds **13a–c** were separated from the reaction filtrate and recrystallized from ethanol. The physical and spectral data of compounds **13a–c** are as follows:

2-(*Aminomethyleneamino*)-4-(4-chlorophenyl)-4H-pyrano [3,2-h]quinoline-3-carbonitrile (**13a**) Colorless needles from ethanol; m.p. 230–232 °C; 38 %; IR (KBr) v (cm⁻¹): 3335, 3300, 3178 (NH₂), 3046, 3009, 2876 (CH), 2194 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.94 (s, 1H, N=CH), 8.09–7.02 (m, 9H, aromatic), 5.04 (bs, 2H, NH₂), 4.85 (s, 1H, H-4); ¹³C NMR (125 MHz) (CDCl₃) δ : 159.32 (N=CH), 150.67 (C-2), 144.95 (C-10b), 142.77 (C-9), 136.13 (C-10a), 135.12 (C-7), 129.17 (C-5), 128.37 (C-6a), 124.06 (C-4a), 122.14 (C-8), 121.15 (C-6), 119.34 (CN), 97.56 (C-3), 41.19 (C-4), 138.08, 133.49, 129.48, 127.00 (aromatic); MS *m*/*z* (%): 362 (M⁺+2, 1), 360 (M⁺, 3), 344 (3), 342 (6), 249 (5), 222 (100), 195 (29), 117 (14), 75 (16); Anal. Calcd for C₂₀H₁₃ClN₄O: C, 66.58; H, 3.63; N, 15.53. Found: C, 66.03; H, 3.63; N, 15.21 %.

2-(Aminomethyleneamino)-4-(4-chlorophenyl)-9-methyl-

4H-pyrano[*3*,2-*h*]*quino*line-3-carbonitrile (**13b**) Colorless needles from ethanol; m.p. 260–261 °C; 39 %; IR (KBr) v (cm⁻¹): 3463, 3340, 3200 (NH₂), 3060, 3025, 2836 (CH), 2188 (CN); ¹H NMR (500 MHz) (DMSO-d₆) δ : 8.24 (s, 1H, N=CH), 8.20–7.12 (m, 8H, aromatic), 7.18 (bs, 2H, NH₂, cancelled by D₂O), 4.99 (s, 1H, H-4), 2.71 (s, 3H, CH₃); ¹³C NMR (125 MHz) (DMSO-d₆) δ : 162.51 (N=CH), 160.32 (C-2), 159.08 (C-9), 156.85 (C-10b), 137.56 (C-10a), 136.11 (C-7), 128.65 (C-5), 125.77 (C-6a), 123.51 (C-8), 122.79 (C-4a), 121.41 (C-6), 120.13 (CN), 95.28 (C-3), 40.42 (C-4), 24.97 (CH₃), 142.60, 131.63, 129.52, 126.12 (aromatic); MS *m*/*z* (%): 376 (M⁺+2, 3.84), 374 (M⁺, 10.05), 263 (56), 236 (21), 208 (7), 180 (6), 152 (6), 111 (100), 74 (89), 50 (16); Anal. Calcd for $C_{21}H_{15}ClN_4O$: C, 67.29; H, 4.03; N, 14.95. Found: C, 67.34; H, 3.91; N, 14.83 %.

2-(Aminomethyleneamino)-4-(4-bromophenyl)-9-methyl-

4*H*-pyrano[3,2-*h*]quinoline-3-carbonitrile (**13**c) Colorless needles from ethanol; m.p. 252–253 °C; 40 %; IR (KBr) v (cm⁻¹): 3350, 3322, 3195 (NH₂), 3050, 3010, 2974, 2879 (CH), 2189 (CN); ¹H NMR (500 MHz) (CDCl₃) δ : 8.21 (s, 1H, N=CH), 8.24–7.12 (m, 8H, aromatic), 7.17 (bs, 2H, NH₂), 4.98 (s, 1H, H-4), 2.74 (s, 3H, CH₃); ¹³C NMR (125 MHz) (DMSO-d₆) δ : 162.51 (N=CH), 159.05 (C-2), 156.85 (C-10b), 143.55 (C-9), 136.12 (C-10a), 136.12 (C-7), 129.78 (C-5), 126.13 (C-6a), 125.77 (C-8), 123.51 (C-4a), 120.29 (C-6), 120.18 (CN), 95.22 (C-3), 40.08 (C-4), 137.57, 131.63, 131.85, 122.71 (aromatic); MS *m*/*z* (%): 420 (M⁺+2, 9.21), 418 (M⁺, 10.31), 236 (84), 209 (23), 180 (10), 155 (38), 127 (4), 75 (100), 50 (16); Anal. Calcd for C₂₁H₁₅BrN₄O: C, 60.16; H, 3.61; N, 13.36. Found: 60.21; H, 3.73; N, 13.42 %.

Method (b)

A mixture of **3a,c,d** (0.01 mol) and formamide (20 ml) was stirred at reflux for 3 h. The solvent was removed under vacuum. The solid obtained was recrystallized from benzene to give **8a–c** (m.p. and mixed m.p. are completely identical) yield (71–67 %).

Method (c)

Compound **13a–c** (0.01 mol) was heated under reflux in ethanol (20 ml) and piperidine (0.5 ml) for 3 h to give **8a–c** (m.p. and mixed m.p. are completely identical) yield (58–60 %).

Reaction of the imadate (9a,b) with dimethylamine

Method (a)

A mixture of imadate 9a,b (0.01 mol) and dimethylamine (0.01 mol) in ethanol (30 ml) was stirred at room temperature for 1 h. The solid product was collected and recrystallized from proper solvent to give 10a,b (m.p. and mixed m.p. are completely identical) yield (88–87 %).

Method (b)

A mixture of β -enaminonitrile **3a**,c (0.01 mol), DMF-DPA (0.01 mol), and benzene (30 ml) was refluxed for 3 h. The solvent was removed under reduced pressure and the resulting solid was recrystallized from proper solvent to

give **10a,b** (m.p. and mixed m.p. are completely identical) yield (83–81 %).

Reaction of 10a,b with hydrazine hydrate

Method (a)

A mixture of imidine **10a,b** (0.01 mol) and hydrazine hydrate (0.01 mol) in ethanol (30 ml) was stirred at room temperature or reflux for 1 h. The solid product was collected and recrystallized from proper solvent to give **10a,b** (m.p. and mixed m.p. are completely identical) yield (80–81 %).

Method (b)

A mixture of imidine **10a**,**b** (0.01 mol), hydrazine hydrate (0.01 mol), and *p*-toluenesulfonic acid (0.01 mol) in toluene (30 ml) was heated under reflux for 7 h. The solid product was collected and recrystallized from proper solvent to give **10a**,**b** (m.p. and mixed m.p. are completely identical) yield (78–80 %).

Antitumor screening

Cell culture

MCF-7, HCT, and HepG-2 cells were grown on RPMI-1640 medium supplemented with 10 % inactivated fetal calf serum and 50 µg/ml gentamycin. Vero cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % heat-inactivated fetal calf serum, 1 % L-glutamine, HEPES buffer, and 50 µg/ml gentamycin. All cells were maintained at 37 °C in a humidified atmosphere with 5 % CO₂ and were subcultured two to three times a week.

Cytotoxicity evaluation using viability assay

The in vitro cytotoxicity activity was studied against three cell lines: MCF-7, HCT, and HepG-2 using the colorimetric MTT assay (Mossman, 1983). The cells were seeded in 96-well microtiter plate at a cell concentration of 1×10^4 cells per well in 100 µl of growth medium. Fresh medium containing different concentrations of the test sample was added after 24 h of seeding. Serial twofold dilutions of the metabolites were added to confluent cell monolayers. The microtiter plates were incubated at 37 °C in a humidified incubator with 5 % CO₂ for a period of 48 h. Three wells were used for each concentration of the test sample and with or without DMSO. The little percentage of

DMSO present in the wells (maximal 0.1 %) was not found to affect the experiment. After incubation of the cells for 24 h at 37 °C, various concentrations of sample were added, and the incubation was continued for 48 h and viable cells yield was determined by a colorimetric MTT method.

In brief, after the end of the incubation period, crystal violet solution (1 %) was added to each well for 30 min. The stain was removed and the plates were rinsed using tap water until all excess stain was removed. Glacial acetic acid was then added to all wells and mixed thoroughly, and the plates were read on ELISA reader, using a test wavelength of 490 nm. Treated samples were compared with the control in the absence of the tested samples. All experiments were carried out in triplicate. The cytotoxic effect of each tested compound was calculated.

Acknowledgments This study was supported by King Abdulaziz City for Science and Technology (KACST), No. A-S-11-0560. The authors deeply thank the Regional Center for Mycology & Biotechnology (RCMP), Al-Azhar University for carrying out the antitumor study and Mr. Ali Y. A. Alshahrani for making the ¹H NMR and ¹³C NMR samples.

References

- Abd-El-Aziz AS, El-Agrody AM, Bedair AH, Christopher Corkery T, Ata A (2004) Synthesis of hydroxyquinoline derivatives, aminohydroxychromene, aminocoumarin and their antimicrobial activities. Heterocycles 63:1793–1812
- Abd-El-Aziz AS, Mohamed HM, Mohammed S, Zahid S, Ata A, Bedair AH, El-Agrody AM, Harvey PD (2007) Synthesis of novel coumarin and benzocoumarin derivatives and their biological and photophysical studies. J Heterocycl Chem 44:1287–1300
- Al-Ghamdi AM, Abd EL-Wahab AHF, Mohamed HM, El-Agrody AM (2012) Synthesis and antitumor activities of 4*H*-pyrano[3,2*h*]quinoline-3-carbonitrile, 7*H*-pyrimido-[4',5':6,5]pyrano[3,2*h*]quinoline, and 14*H*-pyrimido[4',5':6,5]pyrano[3,2-*h*][1,2,4]triazolo[1,5-*c*]quinoline derivatives. Lett Drug Des Discov 9:459–470
- Andrew T, Marilena V, Maria G, Aphrodite E, Constantine I, Anna K, Pandelis AA, Dimitri M, Christos R (2007) Symmetrical derivatives of C2-substituted pyrrolo[2,3-f]-quinolines: synthesis, cytotoxicity and drug delivery studies. Lett Drug Des Discov 4:87–91
- Badawey ES, Kappe T (1997) Potential antineoplastics. Synthesis and cytotoxicity of certain 4-chloro-3-(2-chloroethyl)-2-methylquinolines and related derivatives. Eur J Med Chem 32:815–822
- Bedair AH, El-Hady NA, Abd El-Latif MS, Fakery AH, El-Agrody AM (2000) 4-Hydroxycoumarin in heterocyclic synthesis part III: synthesis of some new pyrano[2,3-*d*]pyrimidine, 2-substituted[1,2,4]triazolo[1,5-*c*]pyrimidine and pyrimido[1,6-*b*][1,2,4] triazine derivatives. IL Farmaco 55:708–714
- Bedair AH, Emam HA, El-Hady NA, Ahmed KAR, El-Agrody AM (2001) Synthesis and antimicrobial activities of novel naphtho[2,1-*b*]pyran, pyrano[3,2-*d*]pyrimidine and pyrano[3,2*e*][1,2,4]triazolo[2,3-*c*]pyrimidine derivatives. IL Farmaco 56:965–973

- Broch S, Hénon H, Debaud AL, Fogeron ML, Bonnefoy-Bérard N, Anizon F, Moreau P (2010) Synthesis and biological activities of new di- and trimeric quinoline derivatives. Bioorg Med Chem 18:7132–7143
- Chang FS, Chen W, Wangb C, Tzeng CC, Chen YL (2010) Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinyl-quinoline derivatives. Bioorg Med Chem 18:124–132
- Desai NC, Dodiya AM (2011) Conventional and microwave techniques for synthesis and antimicrobial studies of novel 1-[2-(2-chloro(3-quinolyl))-5-(4-nitrophenyl)-(1,3,4-oxadiazolin-3-yl)]-3-(aryl)prop-2-en-1-ones. Med Chem Res. doi: 10.1007/s00044-011-9670-9
- Eid FA, Bedair AH, Emam HA, Mohamed HM, El-Agrody AM (2003) Reaction of activated nitriles with methanolic piperidine and synthesis of 1h-benzo[*f*]chromene, diazabenzo[*j*]anthracene and diazabenzo[*a*][1,2,4]triazolo[*j*]anthracene derivatives. Al-Azhar Bull Sci 14:311–342
- El-Agrody AM (1994) Condensation reactions of α -cyanocinnamonitriles with naphthols: synthesis of naphthopyranopyrimidines and a naphthopyranone. J Chem Res (S) 280–281
- El-Agrody AM, Al-Ghamdi AM (2011) Synthesis of certain novel 4*H*-pyrano[3,2-*h*]quinoline derivatives. Arkivoc xi:134–46
- El-Agrody AM, Emam HA, El-Hakim MH, Abd El-Latif MS, Fakery AH (1997a) Activated nitriles in heterocyclic synthesis: synthesis of pyrano[3,2-*d*]pyrimidine and pyrano[3,2-*e*][1,2,4]triazol-o[1,5-*c*]pyrimidine derivatives. J Chem Res (S) 320–321
- El-Agrody AM, Emam HA, El-Hakim MH, Abd El-Latif MS, Fakery AH (1997b) Activated nitriles in heterocyclic synthesis: synthesis of pyrano[3,2-d]pyrimidine and pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives. J Chem Res (M) 2039–2048
- El-Agrody AM, El-Hakim MH, Abd El-Latif MS, Fakery AH, El-Sayed ESM, El-Ghareab KA (2000) Synthesis of pyrano[2, 3-d]pyrimidine and pyrano[3,2-e][1,2,4]triazolo[2,3-c]-pyrimidine derivatives with promising antimicrobial activities. Acta Pharm 50:111–120
- El-Agrody AM, Abd El-Latif MS, El-Hady NA, Fakery AH, Bedair AH (2001) Heteroaromatization with 4-hydroxycoumarin part II: synthesis of some new pyrano[2,3-*d*]pyrimidine, [1,2,4]triazolo[1,5-*c*]pyrimidine and pyrimido[1,6-*b*][1,2,4]-triazine derivatives. Molecules 6:519–527
- El-Agrody AM, Eid FA, Emam HA, Mohamed HM, Bedair AH (2002) Synthesis of 9-methoxy and 9-acetoxy-3-amino-1-(4-methoxyphenyl)-1*H*-benzo[*f*]chromene-2-carbonitriles via 2-(iminopiperidin-1-yl-methyl)-3-(4-methoxyphenyl)acrylonitrile as intermediate. Z Naturforsch Teil B 57:579–585
- El-Agrody AM, Sabry NM, Motlaq SS (2011) Synthesis of some new 2-substituted 12*H*-chromeno[3,2-*e*][1,2,4]triazolo[1,5-*c*]pyrimidine, 3-ethoxycarbonyl-12*H*-chromeno[3,2-*e*]-[1,2,4]triazolo[1,5-*c*] pyrimidine-2-one, ethyl 2-formylamino\acetylamino-4*H*-chromene-3-carboxylate and some of their antimicrobial activities. J Chem Res 35:77–83
- El-Agrody AM, Khattab ESAEH, Fouda AM, Al-Ghamdi AM (2012) Synthesis, antimicrobial and antitumor activities of certain novel 2-amino-9-(4-halostyryl)-4*H*-pyrano[3,2-*h*]-quinoline tives. Med Chem Res. doi:10.1007/s00044-011-9965-x
- Ganesh T, Min J, Thepchatri P, Du Y, Li L, Lewis I, Wilson L, Chiosis HFG, Dingledine R, Liotta D, Snyder JP, Sun A (2008) Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): synthesis, biology, and molecular modeling. Bioorg Med Chem 16:6903–6910
- Guo RH, Zhang Q, Ma YB, Huang XY, Luo J, Wang LJ, Geng CA, Zhang XM, Zhou J, Jiang ZY, Chen JJ (2011) Synthesis and biological assay of 4-aryl-6-chloroquinoline derivatives as novel non-nucleoside anti-HBV agents. Bioorg Med Chem 19:1400–1408

- Harris CR, Thorarensen A (2004) Advances in the discovery of novel antibacterial agents during the year 2002. Curr Med Chem 11:2213–2243
- Jampilek J, Musiol R, Pesko M, Kralova K, Vejsova M, Carroll J, Coffey A, Finster J, Tabak D, Niedbala H, Kozik V, Polanski J, Csollei J, Dohnal J (2009) Ring-substituted 4-hydroxy-1 *H*-quinolin-2-ones: preparation and biological activity. Molecules 14:1145–1159
- Khafagy MM, Abd El-Wahab AHF, Eid FA, El-Agrody AM (2002) Synthesis of halogen derivatives of benzo[*h*]cheromene and benzo[*a*]anthracene with promising antimicrobial activities. IL Farmaco 57:715–722
- Larghi EL, Bohn ML, Kaufman TS (2009) Aaptamine and related products. Their isolation, chemical syntheses and biological activity. Tetrahedron 65:4257–4282
- Mossman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
- Mrozek-Wilczkiewicz A, Kalinowski DS, Musiol R, Finster J, Szurko A, Serafin K, Knas M, Kamalapuram SK, Kovacevic Z, Jampilek J, Ratuszna A, Rzeszowska-Wolny J, Richardson DR, Polanski J (2010) Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorg Med Chem 18:2664–2671
- Musiol R, Jampilek J, Buchta V, Silva L, Niedbala H, Podeszwa B, Palka A, Majerz-Maniecka K, Oleksyn B, Polanski J (2006) Antifungal properties of new series of quinoline derivatives. Bioorg Med Chem 14:3592–3598
- Musiol R, Jampilek J, Kralova K, Richardson DR, Finster J, Kalinowski D, Podeszwa B, Niedbala H, Palka A, Polanski J (2007) Investigating biological activity spectrum for novel quinoline analogues. Bioorg Med Chem 15:1280–1288
- Musiol R, Tabak D, Niedbala H, Podeszwa B, Jampilek J, Kralova K, Dohnal J, Finster J, Mencel A, Polanski J (2008) Investigating biological activity spectrum for novel quinoline analogues 2: hydroxyquinolinecarboxamides with photosynthesis-inhibiting activity. Bioorg Med Chem 16:4490–4499
- Narender P, Srinivas U, Ravinder MCh, Ramesh BK, Gangadasu B, Murthy USN, Jayathirtha RV (2006) Synthesis of multisubstituted quinolines from Baylis–Hillman adducts obtained from substituted 2-chloronicotinaldehydes and their antimicrobial activity. Bioorg Med Chem 14:4600–4609
- Pommier Y, Johnson AA, Marchand C (2005) Integrase inhibitors to treat HIV/Aids. Nat Rev Drug Discov 4:236–248
- Rahman AU, Choudhary MI, Thomsen WJ (2001) Bioassay technique for drug development. Harwood Academic Publishers, Chur
- Ramesh RD, Manian RS, Raghunathan R, Sainath S, Raghunathan M (2009) Synthesis and antibacterial property of quinolines with potent DNA gyrase activity. Bioorg Med Chem 17:660–666
- Righi G, Ciambrone S, Bonini C, Campaner P (2008) Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir. Bioorg Med Chem 16:902–908
- Sabry NM, Mohamed HM, Khattab Essam Shawky AEH, Motlaq SS, El-Agrody AM (2011) Synthesis of 4*H*-chromene, coumarin, 12*H*-chromeno[2,3-*d*]pyrimidine derivatives and some of their antimicrobial and cytotoxicity activities. Eur J Med Chem 46:765–772
- Salaheldin AM, Oliveira-Campos AMF, Rodrigues L (2008) 3-Aminopyrroles and their application in the synthesis of pyrrolo[3,2-d]pyrimidine (9-deazapurine) derivatives. Arkivoc xiv:180–190
- Saugues E, Nauton L, Théry V, Anizon F, Moreau P (2011) Synthesis and molecular modeling study of new trimeric quinoline derivatives. Bioorg Chem 39:143–150

- Sayed AZ, El-Hady NA, El-Agrody AM (2000) Condensation of α-cyanocinnamonitriles with 6-bromo-2-naphthols: synthesis of pyrano[2,3-*d*]pyrimidine and pyrano[3,2-*e*][1,2,4]-triazolo[2,3*c*]pyrimidine derivatives. J Chem Res 164–166
- Tacconi G, Gatti G, Desimoni G, Messori V (1980) A new route to 4H-pyrano[2, 3-c]pyrazoles. J Prakt Chem 322:831–834
- Thomas LJ, Roy K (2008) Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur J Med Chem 43:81–92
- Thomas KD, Adhikari AV, Shetty NS (2010) Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety. Eur J Med Chem 45:3803–3810
- Xin-Hua L, Jing Z, An-na Z, Bao-An S, Hai-Liang Z, Lin-Shan b, Pinaki SB, Chun-Xiu P (2009) Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4yl)-3-(2-substitued-phenyl)-4,5-dihydro-1*H*-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives. Bioorg Med Chem 17:1207–1213
- Zouhiri F, Danet M, Bernard C, Normand-Bayle M, Mouscadet JF, Leh H, Thomas CM, Mbemba G, d'Angelo J, Desmaele D (2005) HIV-1 replication inhibitors of the styrylquinoline class: introduction of an additional carboxyl group at the C-5 position of the quinoline. Tetrahedron Lett 46:2201–2205